MECA-79+ TA-HEVs were first observed in mice following various treatments such as adoptive transfer of CD8+ T cells, administration of tumor-targeted LTα or genetic depletion of Foxp3+ regulatory T cells (Tregs) [282–285]. The gene discussed is CD8A; the disease is neoplasm.